Novel Approaches in the Systemic Management of High-Risk Prostate Cancer

Gómez-Aparicio, María Antonia; López-Campos, Fernando; Lozano, A.; Maldonado, X.; Caballero, B.; Zafra, Juan; Suarez, Vladamir; Moreno, Elena; Arcangeli, Stefano; Scorsetti, Marta; Couñago, Felipe

doi:10.1016/j.clgc.2023.06.001

Cited by 2 publications

(1 citation statement)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, PCa patients are typically categorized into risk strata predicated on the prostate-specific antigen (PSA) concentration, clinical T classification, and biopsy-derived Gleason score (GS) [5,6]. High-risk PCa constitutes 20-30% of PCa diagnoses [7,8].…”

Section: Introductionmentioning

confidence: 99%

Identification of Early Biochemical Recurrence Predictors in High-Risk Prostate Cancer Patients Treated with Carbon-Ion Radiotherapy and Androgen Deprivation Therapy

Utsumi,

Suzuki,

Ishikawa

et al. 2023

Current Oncology

View full text Add to dashboard Cite

The aim of this retrospective study was to identify clinical predictors of early biochemical recurrence (BCR) in patients with high-risk prostate cancer (PCa) treated with carbon-ion radiotherapy (CIRT) and androgen deprivation therapy (ADT). A total of 670 high-risk PCa patients treated with CIRT and ADT were included in the study. Early BCR was defined as recurrence occurring during adjuvant ADT after CIRT or within 2 years after completion of ADT. Univariate and multivariate analyses were performed to identify clinical predictors of early BCR. Patients were also classified according to the Systemic Therapy in Advancing or Metastatic Prostate cancer (STAMPEDE) PCa classification. Early BCR was observed in 5.4% of the patients. Multivariate analysis identified clinical T3b stage and ≥75% positive biopsy cores as clinical predictors of early BCR after CIRT and ADT. The STAMPEDE PCa classification was also significantly associated with early BCR based on univariate analysis. These predictors can help clinicians identify patients who are at risk of early BCR. In the future, combination therapy of ADT with abiraterone may be an option for high-risk PCa patients who are at risk of early BCR, based on the results of the STAMPEDE study.

show abstract